Administration of rabies immunoglobulin: Improving evidence-based guidance for wound infiltration

P. Brandon Bookstaver; Peter Akpunonu; Huy Binh Nguyen; Joshua T. Swan; Gavin T. Howington

doi:10.1002/phar.2604

Administration of rabies immunoglobulin: Improving evidence-based guidance for wound infiltration

P. Brandon Bookstaver, Peter Akpunonu, Huy Binh Nguyen, Joshua T. Swan, Gavin T. Howington

Research output: Contribution to journal › Comment/debate

6 Scopus citations

Abstract

Rabies virus causes a fatal infection of the brain and spinal cord, accounting for approximately 59,000 deaths globally each year. Rabies postexposure prophylaxis (PEP), including both rabies immunoglobulin (RIG) and vaccination, is administered to 55,000 patients annually in the United States. With a nearly 100% case fatality rate, the optimal administration of rabies PEP cannot be understated. Updated rabies PEP guidelines issued by the World Health Organization (WHO) in 2018 recognized that local wound infiltration of RIG is the primary mechanism of protection, and the WHO now recommends only infiltration of wounds without distal intramuscular injection. We highlight potential points of failure involving wound infiltration of RIG, small-volume doses, and large-volume doses that may lead to suboptimal care and discuss implications of recent shifts toward evidence-based guidelines using wound type and RIG volumes.

Original language	English
Pages (from-to)	644-648
Number of pages	5
Journal	Pharmacotherapy
Volume	41
Issue number	8
DOIs	https://doi.org/10.1002/phar.2604
State	Published - Aug 2021

Bibliographical note

Funding Information:
PBB, PA, and GTH received stipends and JTS’s employer received a stipend from Kedrion Biopharma, Inc. for participation in a human rabies immune globulin advisory board that directly supported this manuscript. JTS receives research funding from Kedrion Biopharma, Inc. and Grifols Biologics, LLC for rabies postexposure prophylaxis research. PBB has received funding from TRC Healthcare for antimicrobial stewardship content development and speaking; received speaker's honorarium from PTCe for discussion on influenza management; received speaker's honorarium from Physicians’ Education Resources, LLC for discussion on COVID‐19 monoclonal antibody therapy. HBN is an employee of Kedrion Biopharma Inc.

Publisher Copyright:
© 2021 Pharmacotherapy Publications, Inc.

Keywords

guidelines
immunoglobulins
implementation
medication error
rabies

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/phar.2604

Cite this

@article{553391f548024b0e85ecc91403f22927,

title = "Administration of rabies immunoglobulin: Improving evidence-based guidance for wound infiltration",

abstract = "Rabies virus causes a fatal infection of the brain and spinal cord, accounting for approximately 59,000 deaths globally each year. Rabies postexposure prophylaxis (PEP), including both rabies immunoglobulin (RIG) and vaccination, is administered to 55,000 patients annually in the United States. With a nearly 100% case fatality rate, the optimal administration of rabies PEP cannot be understated. Updated rabies PEP guidelines issued by the World Health Organization (WHO) in 2018 recognized that local wound infiltration of RIG is the primary mechanism of protection, and the WHO now recommends only infiltration of wounds without distal intramuscular injection. We highlight potential points of failure involving wound infiltration of RIG, small-volume doses, and large-volume doses that may lead to suboptimal care and discuss implications of recent shifts toward evidence-based guidelines using wound type and RIG volumes.",

keywords = "guidelines, immunoglobulins, implementation, medication error, rabies",

author = "Bookstaver, {P. Brandon} and Peter Akpunonu and Nguyen, {Huy Binh} and Swan, {Joshua T.} and Howington, {Gavin T.}",

note = "Funding Information: PBB, PA, and GTH received stipends and JTS{\textquoteright}s employer received a stipend from Kedrion Biopharma, Inc. for participation in a human rabies immune globulin advisory board that directly supported this manuscript. JTS receives research funding from Kedrion Biopharma, Inc. and Grifols Biologics, LLC for rabies postexposure prophylaxis research. PBB has received funding from TRC Healthcare for antimicrobial stewardship content development and speaking; received speaker's honorarium from PTCe for discussion on influenza management; received speaker's honorarium from Physicians{\textquoteright} Education Resources, LLC for discussion on COVID‐19 monoclonal antibody therapy. HBN is an employee of Kedrion Biopharma Inc. Publisher Copyright: {\textcopyright} 2021 Pharmacotherapy Publications, Inc.",

year = "2021",

month = aug,

doi = "10.1002/phar.2604",

language = "English",

volume = "41",

pages = "644--648",

number = "8",

}

TY - JOUR

T1 - Administration of rabies immunoglobulin

T2 - Improving evidence-based guidance for wound infiltration

AU - Bookstaver, P. Brandon

AU - Akpunonu, Peter

AU - Nguyen, Huy Binh

AU - Swan, Joshua T.

AU - Howington, Gavin T.

N1 - Funding Information: PBB, PA, and GTH received stipends and JTS’s employer received a stipend from Kedrion Biopharma, Inc. for participation in a human rabies immune globulin advisory board that directly supported this manuscript. JTS receives research funding from Kedrion Biopharma, Inc. and Grifols Biologics, LLC for rabies postexposure prophylaxis research. PBB has received funding from TRC Healthcare for antimicrobial stewardship content development and speaking; received speaker's honorarium from PTCe for discussion on influenza management; received speaker's honorarium from Physicians’ Education Resources, LLC for discussion on COVID‐19 monoclonal antibody therapy. HBN is an employee of Kedrion Biopharma Inc. Publisher Copyright: © 2021 Pharmacotherapy Publications, Inc.

PY - 2021/8

Y1 - 2021/8

N2 - Rabies virus causes a fatal infection of the brain and spinal cord, accounting for approximately 59,000 deaths globally each year. Rabies postexposure prophylaxis (PEP), including both rabies immunoglobulin (RIG) and vaccination, is administered to 55,000 patients annually in the United States. With a nearly 100% case fatality rate, the optimal administration of rabies PEP cannot be understated. Updated rabies PEP guidelines issued by the World Health Organization (WHO) in 2018 recognized that local wound infiltration of RIG is the primary mechanism of protection, and the WHO now recommends only infiltration of wounds without distal intramuscular injection. We highlight potential points of failure involving wound infiltration of RIG, small-volume doses, and large-volume doses that may lead to suboptimal care and discuss implications of recent shifts toward evidence-based guidelines using wound type and RIG volumes.

AB - Rabies virus causes a fatal infection of the brain and spinal cord, accounting for approximately 59,000 deaths globally each year. Rabies postexposure prophylaxis (PEP), including both rabies immunoglobulin (RIG) and vaccination, is administered to 55,000 patients annually in the United States. With a nearly 100% case fatality rate, the optimal administration of rabies PEP cannot be understated. Updated rabies PEP guidelines issued by the World Health Organization (WHO) in 2018 recognized that local wound infiltration of RIG is the primary mechanism of protection, and the WHO now recommends only infiltration of wounds without distal intramuscular injection. We highlight potential points of failure involving wound infiltration of RIG, small-volume doses, and large-volume doses that may lead to suboptimal care and discuss implications of recent shifts toward evidence-based guidelines using wound type and RIG volumes.

KW - guidelines

KW - immunoglobulins

KW - implementation

KW - medication error

KW - rabies

UR - http://www.scopus.com/inward/record.url?scp=85109139703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109139703&partnerID=8YFLogxK

U2 - 10.1002/phar.2604

DO - 10.1002/phar.2604

M3 - Comment/debate

C2 - 34224157

AN - SCOPUS:85109139703

SN - 0277-0008

VL - 41

SP - 644

EP - 648

JO - Pharmacotherapy

JF - Pharmacotherapy

IS - 8

ER -

Administration of rabies immunoglobulin: Improving evidence-based guidance for wound infiltration

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this